Showing results (71-80 of 77) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.Integrated Environmental Assessment and Management|January 5, 2019
Scientific integrity issues in Environmental Toxicology and Chemistry: Improving research reproducibility, credibility, and transparencyChristopher A Mebane, John P Sumpter, Anne Fairbrother, et al.Bioorganic & Medicinal Chemistry Letters|June 20, 2001
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitorsM R Michaelides, J F Dellaria, J Gong, et al.Journal of Medicinal Chemistry|January 5, 2002
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitorsCarol K Wada, James H Holms, Michael L Curtin, et al.Implementation Science : IS|October 23, 2015
Protocol for the development of a CONSORT-equity guideline to improve reporting of health equity in randomized trialsVivian Welch, J Jull, J Petkovic, et al.Bioorganic & Medicinal Chemistry Letters|June 20, 2001
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770M L Curtin, A S Florjancic, H R Heyman, et al.BMJ Open|September 28, 2017
When is a randomised controlled trial health equity relevant? Development and validation of a conceptual frameworkJ Jull, M Whitehead, M Petticrew, et al.Pageof 8